Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Vera Therapeutics (Nasdaq: VERA) announced that on December 2, 2025 its Compensation Committee granted inducement awards under the 2024 Inducement Plan to seven new employees. The awards include non-qualified stock options to purchase 42,000 shares and restricted stock units underlying 21,000 shares of Class A common stock.

Each option has an exercise price of $37.25 (Vera's closing price on December 2, 2025) and vests over four years (25% after one year, then monthly over 36 months). RSUs vest over four years with 25% vesting on each anniversary of November 20, 2025. Awards are subject to the Inducement Plan and applicable award agreements.

News Market Reaction – VERA

+0.29%

25 alerts

+0.29% Session close to close

+3.8% Peak in 2 hr 37 min

$2.95B Market Cap

0.5x Rel. Volume

In the Dec 8 session, VERA gained 0.29%, reflecting a mild positive market reaction. Argus tracked a peak move of +3.8% during that session. Our momentum scanner triggered 25 alerts that day, indicating elevated trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement details equity inducement grants to 7 new employees, including 42,000 non-qualifie...

Analysis

This announcement details equity inducement grants to 7 new employees, including 42,000 non-qualified stock options at $37.25 and 21,000 RSUs, all vesting over 4 years. It follows prior inducement awards under the 2024 Inducement Plan and comes after significant milestones like the atacicept BLA submission. Investors may track ongoing use of equity compensation, insider Form 4 activity, and future clinical or regulatory updates to contextualize these routine HR-related grants.

Key Figures

Current share price: $42.92 Stock options granted: 42,000 shares RSUs granted: 21,000 shares +5 more

8 metrics

Current share price $42.92 Pre-news price on publication date

Stock options granted 42,000 shares Non-qualified stock options under 2024 Inducement Plan

RSUs granted 21,000 shares Restricted stock units under 2024 Inducement Plan

New employees 7 employees Recipients of inducement awards on December 2, 2025

Option exercise price $37.25 Equal to closing price on December 2, 2025

Option vesting period 4 years 25% after one year, then monthly over 36 months

RSU vesting period 4 years 25% annually on each anniversary of November 20, 2025

Market cap $2,637,672,003 Market capitalization before this announcement

Historical Context

5 past events · Latest: Nov 26 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Nov 26	Board appointment	Positive	+13.3%	Veteran biotech executive James R. Meyers joined the board to support commercialization.
Nov 24	Investor conferences	Neutral	+2.7%	Participation in Evercore and Citi healthcare conferences with fireside chats and 1x1 meetings.
Nov 10	Investor summit	Neutral	+14.7%	Presentation and 1x1 meetings at TD Cowen Immunology & Inflammation Summit.
Nov 07	BLA submission	Positive	-4.1%	BLA filed via FDA Accelerated Approval Program for atacicept in IgA nephropathy with strong Phase 3 data.
Nov 07	Inducement grants	Neutral	-4.1%	Prior inducement stock options and RSUs granted under the 2024 Inducement Plan.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent news shows strong positive reactions to management and conference updates, while major clinical/regulatory milestones and prior inducement grants have seen negative or mixed price responses.

Recent Company History

Over the last few months, Vera reported board strengthening on Nov 26, investor conference participation in early December, and a BLA submission supported by positive Phase 3 ORIGIN 3 data on Nov 7. A prior inducement grant announcement on Nov 4 coincided with a negative move despite being routine. Against this backdrop, the new Dec 2 inducement awards look like a continuation of ongoing hiring and equity-compensation activity rather than a new strategic shift.

Key Terms

nasdaq listing rule 5635(c)(4), non-qualified stock options, restricted stock units, rsus, +1 more

5 terms

nasdaq listing rule 5635(c)(4) regulatory

"approved the awards as an inducement material ... in accordance with Nasdaq Listing Rule 5635(c)(4)."

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

non-qualified stock options financial

"granted inducement awards consisting of non-qualified stock options to purchase 42,000 shares..."

Non-qualified stock options are a type of employee benefit that gives individuals the right to buy company shares at a set price, usually lower than the market value, within a certain period. Unlike other options that may have special tax advantages, these options are taxed as income when exercised, which can affect how much money the employee or investor ultimately gains. They are important because they can influence company compensation strategies and impact the financial outcomes for employees and investors.

restricted stock units financial

"and restricted stock units (RSUs) underlying 21,000 shares of Class A common stock..."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

rsus financial

"and restricted stock units (RSUs) underlying 21,000 shares of Class A common stock..."

RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.

class a common stock financial

"options to purchase 42,000 shares of Class A common stock and restricted stock units..."

Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BRISBANE, Calif., Dec. 05, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on December 2, 2025, the Compensation Committee of the Board of Directors of Vera Therapeutics granted inducement awards consisting of non-qualified stock options to purchase 42,000 shares of Class A common stock and restricted stock units (RSUs) underlying 21,000 shares of Class A common stock to seven (7) new employees under the Vera Therapeutics, Inc. 2024 Inducement Plan (Inducement Plan). The Compensation Committee approved the awards as an inducement material to the new employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4).

Each stock option granted on December 2, 2025 has an exercise price per share equal to $37.25, Vera Therapeutics’ closing trading price on December 2, 2025. Each stock option will vest over four years, with 25% of the underlying shares vesting on the first anniversary of the applicable vesting commencement date and the balance of the underlying shares vesting monthly thereafter over 36 months, subject to the new employee’s continued service relationship with Vera Therapeutics through the applicable vesting dates. Each of the RSU awards will vest over four years, with 25% of the underlying shares vesting on each anniversary of November 20, 2025, subject to the new employee’s continued service relationship with Vera Therapeutics through the applicable vesting dates. The awards are subject to the terms and conditions of the Inducement Plan and the terms and conditions of an applicable award agreement covering the grant.

About Vera Therapeutics
Vera Therapeutics is a late clinical-stage biotechnology company focused on developing treatments for serious immunological diseases. Vera Therapeutics’ mission is to advance treatments that target the source of disease in order to change the standard of care for patients. Vera Therapeutics’ lead product candidate is atacicept, a fusion protein self-administered at home as a subcutaneous once weekly injection that blocks both B-cell Activating Factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL), which stimulate B cells to produce autoantibodies contributing to certain autoimmune diseases, including immunoglobulin A nephropathy (IgAN) and lupus nephritis. Beyond IgAN, Vera Therapeutics is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove clinically meaningful. In addition, Vera Therapeutics holds an exclusive license agreement with Stanford University for a novel, next generation fusion protein targeting BAFF and APRIL, known as VT-109, with wide therapeutic potential across the spectrum of B-cell-mediated diseases. Vera Therapeutics is also developing MAU868, a monoclonal antibody designed to neutralize infection with BK virus, which can have devastating consequences in kidney transplant recipients. Vera Therapeutics retains all global developmental and commercial rights to atacicept, VT-109 and MAU868. For more information, please visit www.veratx.com.

For more information, please contact:

Investor Contact:
Joyce Allaire
LifeSci Advisors
212-915-2569
jallaire@lifesciadvisors.com

Media Contact:
Debra Charlesworth
Vera Therapeutics
415-854-8051
corporatecommunications@veratx.com

FAQ

What inducement awards did Vera Therapeutics (VERA) grant on December 2, 2025?

Vera granted non-qualified stock options for 42,000 shares and RSUs for 21,000 shares to seven new employees.

What is the exercise price of the stock options Vera Therapeutics (VERA) granted on December 2, 2025?

Each option has an exercise price of $37.25, the closing price on December 2, 2025.

How do the Vera Therapeutics (VERA) option grants vest?

Options vest over four years: 25% after one year, then the remaining shares vest monthly over 36 months, subject to continued service.

What is the vesting schedule for the RSUs Vera Therapeutics (VERA) granted?

Each RSU award vests over four years with 25% vesting on each anniversary of November 20, 2025, subject to continued service.

How many employees received inducement awards from Vera Therapeutics (VERA) on December 2, 2025?

Seven new employees received the inducement awards.